# Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

> **NCT01109615** · PHASE2 · TERMINATED · sponsor: **Vejle Hospital** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01109615
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2011-08
- **Final completion:** 2012-03
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Lacking effect of treatment
- **Last updated:** 2012-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01109615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01109615, "Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01109615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*